News Releases

2014

Dec.26.2014 Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration(134KB)
Dec.19.2014 ONO AND GILEAD ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP BTK INHIBITOR, ONO-4059, FOR THE TREATMENT OF B-CELL MALIGNANCIES AND OTHER DISEASES(36.2KB)
Dec.11.2014 ONO Establishes a Local Subsidiary in Taiwan(60.6KB)
Dec.10.2014 ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors(37.4KB)
Dec.10.2014 Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma(117KB)
Nov.19.2014 Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naive Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial(85.8KB)
Nov.05.2014 ONO files an application for RIVASTACH® PATCH for adding dosage and administration in Japan(27.8KB)
Nov.05.2014 Announcement on Financial Results for FY2014 2Q
Oct.31.2014 Phase 2 Objective Response Rates and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology(111KB)
Oct.31.2014 Helsinn Group, Switzerland, announced new data on Fatigue from Phase III Trial (ROMANA 1) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology(105KB)
Oct.29.2014 Establishment of GPCR Consortium, a New International Partnership, to Advance Structural Information about G-protein Coupled Receptors(341KB)
Oct.08.2014 Revisions of Consolidated Financial Forecasts(19.2KB)
Oct.07.2014 Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan(36.3KB)
Oct.03.2014 European Medicines Agency Validates the Marketing Authorization Application for Opdivo (Nivolumab) in Non-Small Cell Lung Cancer(77.4KB)
Oct.02.2014 Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union(73.1KB)
Sep.30.2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy® (ipilimumab) Presented at the ESMO 2014 Congress(136KB)
Sep.29.2014 Helsinn Group, Switzerland, announced the results of Phase III Trials (ROMANA 1 and ROMANA 2) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer(144KB)
Sep.02.2014 Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Intravenous Infusion 20 mg/100 mg launches in Japan for Treatment of Unresectable Melanoma(179KB)
Aug.20.2014 Announcement of top-line results from Phase 3 FOCUS Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed and advanced refractory multiple myeloma(81.8KB)
Aug.11.2014 Phase 3 ASPIRE Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed multiple myeloma met primary endpoint (Progression-free survival)(200KB)
Aug.04.2014 Announcement on Financial Results for FY2014 1Q
July.28.2014 Ono and Meiji Seika Pharma enter into an agreement on development and ommercialization of Limaprost in Thailand and Indonesia(26.2KB)
July.24.2014 ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan(85.8KB)
July.11.2014 Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Bristol-Myers Squibb plans for Third Quarter Submission of a Biologics License Application for Previously Treated Advanced Melanoma(236KB)
July.09.2014 Ono Enters into the Collaboration Agreement with the University of Tokyo regarding Access to Ono's Compound Library(29.8KB)
July.04.2014 Human Anti-human PD-1 Monoclonal Antibody "OPDIVO® Intravenous Infusion 20 mg/100 mg" Receives Manufacturing and Marketing Approval in Japan for the Treatment of Unresectable Melanoma(53.2KB)
Jun.27.2014 Notice to Resolutions Passed at the 66th Ordinary General Shareholders' Meeting
Jun.25.2014 2014Fully Human Anti-PD-1 Antibody Nivolumab ("ONO-4538/BMS-936558") Demonstrates Superior Overall Survival Compared to Dacarbazine in Phase 3 First-Line Melanoma Study (CheckMate -066)(177KB)
Jun.17.2014 Termination of the license agreement for ONO-4641 mutually agreed by Ono and Merck(40.4KB)
Jun.05.2014 Notice to Convene the 66th Ordinary General Shareholders' Meeting
Jun.03.2014 Fully Human Anti-PD-1 Antibody “ONO-4538/BMS-936558”Results from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)(70.3KB)
May.23.2014 Glactiv® has obtained the approval of the partial change in the indications of "type 2 diabetes"(28.9KB)
May.23.2014 FORXIGAR® launches in Japan for the treatment of Type 2 diabetes(99.9KB)
May.13.2014 Position and policies concerning the reduction of the minimum investment unit(21.4KB)
May.13.2014 Announcement on Candidates of Members of the Board of Directors and Corporate Officers(38.9KB)
May.13.2014 Announcement on Financial Results for FY2013
Apr.30.2014 Discontinuation of the license agreement for a new therapeutic agent for thrombocytopenia(16.1KB)
Mar.24.2014 FORXIGA® (dapagliflozin) receives regulatory approval in Japan for the treatment of Type 2 diabetes(94.1KB)
Mar.06.2014 ONO establishes an innovative research network called "Orientem Innovation" together with Tohoku University & The University of Tokyo(165KB)
Feb.04.2014 Announcement on Financial Results for FY2013 3Q
Jan.17.2014 Annoucement on CSR Report 2013